UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities and Exchange Act of 1934

Date of Report (Date of earliest reported): ~~May~~April 155, ~~2008~~2010

(Exact name of registrant as specified in charter)

Utah	000-26753	87-0416131
(State or Other Jurisdiction of Incorporation or Organization)	(Commission File Number)	(IRS Employer Identification No.)

~~43 West~~777 ~~33rd Street~~South Flagler Drive, Suite 800

~~New York,~~West ~~New~~Palm ~~York~~Beach, ~~10001~~Florida 33401

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (1-212~~) 695~~-~~3334~~444-1019

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01

Other Events.

~~As previously~~Confirmation ~~announced, on May 4, 2008, shareholders holding a majority~~ of ~~the outstanding~~designation ~~shares~~ of ~~common~~Registered ~~stock~~agent ofAddress ~~Amazon Biotech, Inc. (the “Company”) terminated Simcha Edell~~ and ~~Mechael~~Management ~~Kanovsky as directors of the Company (the “Terminated Directors”)~~Update. The Terminated Directors had previously submitted resignation as executive officers of the Company. Eliyahu BenTal Tolchinsky was appointed by the majority shareholders as director of the Company and was appointed as the Chief Executive Officer and President of the Company. On May 14, 2008, Mr. Kanovsky, the former Chief Executive Officer, filed a Form 8K with the Securities and Exchange Commission challenging the validity of the removal of the Terminated Directors and the resignation of the executive officers. The filing of this Form 8K by Mr. Kanovsky was not valid and was not authorized by the management of the Company.

Reference Amazon Biotech Inc AMZO.OTCBB; B2DA.F.

The company management have designated the registered agent as:

V Corp Services Llc

1760 South 110 East

Suite 1

Salk Lake City Utah 84105

1-888-528-2677

The office USA address is:

777 South Flagler drive

suite 800

West Palm Beach, Florida 33401

The sole director is Chaim. J .Lieberman. Tel 1-212-444-1019.

Email cj@amazonbiotech.com

Please make sure any business including state, transfer agent, accounting, patents, etc have the approval of Chaim. J. Lieberman.

It is important to note. The founder of Amazon Biotech, Inc in 2003 and its legal counsel Spectrum law group and all the state and SEC filings were based on directors being appointed, removed and replaced with majority shareholder vote not with a formal full shareholder meeting. It was based on this precedent that M. Kanovsky was appointed and removed. If Micheal Kanovsky feels that a full formal shareholder meeting was needed then the he never was a director to begin with.

It is further noted that management has a verified signed and witnessed by two witnesses resignation letter from M. Kanovsky.

The company has been unable to move forward due to refusal by M Kanovsky to recognize this. If you are interested to participate in a shareholder meeting to clarify the matter please contact cj@amazonbiotech.com

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	AMAZON BIOTECH, INC.
Date: May 15, 2008	By:	/s/ Eliyahu BenTal Tolchinsky
Date: April 5, 2010	By:	/s/ Chaim. J .Lieberman
		Name: Eliyahu Bental Tolchinsky
		Name: Chaim. J. Lieberman
		Title: CEO

Filing Compare · AMAZON BIOTECH INC